Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce heart failure hospitalisations by more than a third and halve all-cause mortality compared to other glucose-lowering treatments in type 2 diabetes, according to new research presented at the American College of Cardiology’s meeting in Washington.

Sponsor AstraZeneca says the study is “the first large real-world evidence study of its kind” comparing SGLT-2 inhibitors and other type 2 diabetes medicines.

The study used databases from six countries (the US, Norway, Denmark, Sweden, Germany and the UK) to match 154,523 type 2 diabetes patients taking SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with the same number of controls taking other glucose-lowering drugs.

Most patients (87 per cent) did not have a history of cardiovascular disease. There were 961 hospitalisations for heart failure across the six countries. The German database did not yield linked mortality but in the remaining five countries, 1,334 of 215,622 patients died.

Treatment with a SGLT-2 inhibitor reduced hospital-isations for heart failure by 39 per cent (hazard ratio [HR] 0.61) and deaths from any cause by 51 per cent (HR 0.49) compared with other type 2 diabetes medicines. SGLT-2 inhibitors reduced the composite of heart failure hospitalisation or death from any cause by 46 per cent. There was no significant difference by country.

The study did not examine other cardiovascular events, such as myocardial infarction and stroke, or focus on safety. Moreover, the authors also note that experience with SGLT-2 inhibitors “in real-world practice is still relatively short”. Longer-term follow-up is therefore needed to determine whether the benefits are sustained.

Recommended

Study highlights codeine dependence – a problem for pharmacy?

Pharmacies are a common source of codeine for dependent people but only one in 50 users seeks a pharmacist’s support

Statins cut CV mortality

Pravastatin reduces long-term cardiovascular mortality by more a quarter, even in men with markedly raised LDL-C levels

Popular

Proposed Nov concession prices sent to PSNC

PSNC has received a list of proposed concession prices for 52 of the 67 outstanding requests for November

Legislation finally passed on inadvertent dispensing errors

Pharmacy bodies have welcomed the legislation to introduce a new defence for inadvertent dispensing errors

PDA launches charter and campaign for safer pharmacies

The PDA has launched a Safer Pharmacies Charter with the aim of improving patient safety through better working conditio...